CSIMarket Company Name, Ticker, Industry, else..
 
Biogen Inc   (NASDAQ: BIIB)
Other Ticker:  
 
 
Price: $118.8400 $-0.67 -0.561%
Day's High: $119.62 Week Perf: 2.02 %
Day's Low: $ 117.14 30 Day Perf: -16.56 %
Volume (M): 1,538 52 Wk High: $ 238.00
Volume (M$): $ 182,812 52 Wk Avg: $179.08
Open: $119.13 52 Wk Low: $110.04



 Market Capitalization (Millions $) 17,350
 Shares Outstanding (Millions) 146
 Employees 7,570
 Revenues (TTM) (Millions $) 9,676
 Net Income (TTM) (Millions $) 1,632
 Cash Flow (TTM) (Millions $) 1,393
 Capital Exp. (TTM) (Millions $) 360

Biogen Inc
Company Profile: Biogen Inc.

Overview:
Biogen Inc. is a leading global biotechnology company dedicated to discovering, developing, and delivering innovative therapies for neurological and neurodegenerative diseases, as well as other serious medical conditions. Established in 1978, Biogen has a long-standing commitment to transforming scientific discoveries into effective healthcare solutions that improve the lives of patients worldwide.

Core Focus Areas:
Biogen specializes in the treatment of:
- Neurological Disorders: The company is particularly known for its advancements in therapies for multiple sclerosis (MS), spinal muscular atrophy (SMA), and Alzheimer's disease.
- Oncology: Biogen develops therapies for various cancers, focusing on unmet medical needs and innovative treatment options.
- Immunology: The company is engaged in creating novel immunotherapies for autoimmune diseases.

Key Products:
Biogen has developed a robust portfolio of commercial products, which include:
- AVONEX' (Interferon beta-1a): A leading therapy for the treatment of relapsing forms of multiple sclerosis (MS).
- RITUXAN' (rituximab): A targeted therapy used to treat certain types of B-cell non-Hodgkin lymphomas (B-cell NHLs) and other autoimmune disorders.
- ZEVALIN' (ibritumomab tiuxetan): An innovative radioimmunotherapy for treating specific types of B-cell NHLs.
- AMEVIVE' (alefacept): Approved for the treatment of adult patients with moderate-to-severe chronic plaque psoriasis indicating the need for systemic therapy.

Innovation and Research:
Biogen operates several research and development facilities around the globe, focusing on cutting-edge scientific advancements in biotechnology. The companys pipeline features numerous investigational therapies aimed at addressing significant medical challenges in neurology and beyond.

Commitment to Patients:
Biogen is deeply committed to patient access and support, providing resources and programs that help patients navigate their treatment journeys. The companys dedication to healthcare extends to partnerships with healthcare professionals and advocacy groups to enhance patient care and outcomes.

Sustainability and Ethics:
Biogen is also committed to sustainability in its operations, adhering to ethical practices that demonstrate a responsibility to the environment, communities, and stakeholders.

Conclusion:
As a trailblazer in the biotechnology field, Biogen Inc. continues to set new standards in patient care and innovation, driven by a mission to support individuals in their fight against debilitating diseases. With a strong portfolio and a commitment to research and development, Biogen is focused on transforming the landscape of healthcare.


   Company Address: 225 Binney Street Cambridge 2142 MA
   Company Phone Number: 679-2000   Stock Exchange / Ticker: NASDAQ BIIB


Customers Net Income grew by BIIB's Customers Net Profit Margin grew to

35.65 %
2.54 %

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AMGN        2.62% 
BCRX        2.62% 
CHRS   -3.29%    
EXEL   -3.29%    
GILD   -1.11%    
HALO   -1.11%    
• View Complete Report
   



Management Announcement

Biogen?s Bold Leap: New Headquarters and Innovations in Neurodegenerative Therapies Set the Stage for a Healthier Future

Published Mon, Mar 24 2025 11:30 AM UTC

Biogen Inc., a renowned leader in biopharmaceuticals, is embarking on an ambitious journey that could reshape the landscape of both its operational infrastructure and its contributions to the medical sciences. On March 24, 2025, the company unveiled plans for a new global headquarters and innovation hub situated in the heart of Kendall Square, Cambridge, Massachusetts, marki...
Clinical Study

Pioneering Advances in Neurodegenerative and Kidney Transplant Therapies A Look at Lecanemab and Felzartamabs Regu...

Published Fri, Jan 31 2025 8:53 PM UTC

In a rapid evolution of therapeutic prospects, the biopharmaceutical landscape is witnessing significant strides with the recent regulatory reviews and designations surrounding promising treatments. Notably, recent announcements from Eisai Co., Ltd. and Biogen Inc. shed light on their respective advancements in addressing serious health conditions: Alzheimer s disease and ki...
Product Service News

Biogens LEQEMBI Approval and Market Position Navigating Challenges and Opportunities in Alzheimers Treatment

Published Tue, Jan 14 2025 9:51 AM UTC

Biogen Inc. has recently made waves in the biopharmaceutical landscape with its innovative drug LEQEMBI (lecanemab-irmb), following the FDA s acceptance of its Biologics License Application (BLA) for subcutaneous maintenance dosing. This marks a significant advancement in Alzheimer?s disease treatment, particularly highlighting the potential for convenient at-home administra...
Clinical Study

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Sys...

Published Tue, Nov 19 2024 6:01 AM UTC

Advancements in Lupus and SMA Treatments: A Double-Edged Sword for Biogen and UCB Abstract: Recent presentations at significant medical congresses have unveiled promising developments in the treatments of systemic lupus erythematosus (SLE) and spinal muscular atrophy (SMA). The results from the Phase 3 PHOENYCS GO study highlighting the efficacy of dapirolizumab pegol and...
Management Changes

Transition and Innovation: Biogen?s Leadership Shift and Breakthrough in Kidney Transplant Therapy

Published Mon, Oct 28 2024 12:30 PM UTC

In a climate where organizational stability and groundbreaking advancements in medical science are both crucial, Biogen has recently made...






Biogen Inc's Segments
Product net    71.76 % of total Revenue
Product net U S    32.97 % of total Revenue
Product net Rest of World    38.79 % of total Revenue
MS Product    42.74 % of total Revenue
MS Product Revenues U S    22.14 % of total Revenue
MS Product Revenues Rest of World    20.6 % of total Revenue
Fumarate    15.85 % of total Revenue
Fumarate U S    7.1 % of total Revenue
Fumarate Rest of World    8.76 % of total Revenue
TECFIDERA    9.44 % of total Revenue
TECFIDERA U S    1.63 % of total Revenue
TECFIDERA Rest of World    7.81 % of total Revenue
VUMERITY    6.41 % of total Revenue
VUMERITY U S    5.47 % of total Revenue
VUMERITY Rest of World    0.94 % of total Revenue
Interferon    9.63 % of total Revenue
Interferon U S    5.82 % of total Revenue
Interferon Rest of World    3.81 % of total Revenue
AVONEX    7.15 % of total Revenue
AVONEX U S    4.69 % of total Revenue
AVONEX Rest of World    2.46 % of total Revenue
PLEGRIDY    2.49 % of total Revenue
PLEGRIDY U S    1.13 % of total Revenue
PLEGRIDY Rest of World    1.35 % of total Revenue
TYSABRI    16.47 % of total Revenue
TYSABRI U S    9.23 % of total Revenue
TYSABRI Rest of World    7.24 % of total Revenue
FAMPYRA    0.79 % of total Revenue
FAMPYRA Rest of World    0.79 % of total Revenue
Rare Disease Product Revenue    20.07 % of total Revenue
Rare Disease Product Revenue U S    9.75 % of total Revenue
Rare Disease Product Revenue Rest of World    10.32 % of total Revenue
QALSODY    0.45 % of total Revenue
QALSODY U S    0.22 % of total Revenue
QALSODY Rest of World    0.23 % of total Revenue
SPINRAZA    15.47 % of total Revenue
SPINRAZA U S    6.21 % of total Revenue
SPINRAZA Rest of World    9.26 % of total Revenue
Completed technology for SKYCLARYS U S    4.15 % of total Revenue
Completed technology for SKYCLARYS U S U S    3.32 % of total Revenue
Completed technology for SKYCLARYS U S Rest of World    0.83 % of total Revenue
Biosimilars    7.97 % of total Revenue
Biosimilars U S    0.17 % of total Revenue
Biosimilars Rest of World    7.8 % of total Revenue
BENEPALI    4.79 % of total Revenue
BENEPALI Rest of World    4.79 % of total Revenue
IMRALDI    2.19 % of total Revenue
IMRALDI Rest of World    2.19 % of total Revenue
FLIXABI    0.66 % of total Revenue
FLIXABI Rest of World    0.66 % of total Revenue
BYOOVIZ    0.32 % of total Revenue
BYOOVIZ U S    0.17 % of total Revenue
BYOOVIZ Rest of World    0.16 % of total Revenue
TOFIDENCE    0.01 % of total Revenue
TOFIDENCE U S    0.01 % of total Revenue
Other    0.98 % of total Revenue
Other U S    0.9 % of total Revenue
Other Rest of World    0.07 % of total Revenue
ZURZUVAE    0.89 % of total Revenue
ZURZUVAE U S    0.89 % of total Revenue
FUMADERM And ADUHELM    0.09 % of total Revenue
FUMADERM And ADUHELM U S    0.01 % of total Revenue
FUMADERM And ADUHELM Rest of World    0.07 % of total Revenue
Contract manufacturing revenue    9 % of total Revenue
Royalty and other revenue    1.15 % of total Revenue
Contract manufacturing royalty and other revenue    10.15 % of total Revenue
Genentech    0.19 % of total Revenue
Revenue from anti-CD20 therapeutic programs    18.1 % of total Revenue
Royalty Attributed To OCREVUS    14.06 % of total Revenue





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com